// App-Quantinova.ai

16194 2014 AHA : PCSK9 Inhibitor Alirocumab as Add-on to Atorvastatin versus Other Lipid Treatment Strategies in Patients at High CVD Risk: ODYSSEY OPTIONS I

Researchers

Presenter

  • Daniel Gaudet

Principal Investigators

  • Robert Weiss

  • Juan Lima Ruiz

  • Gerald F Watts

  • Ioanna Gouni-Berthold

  • Jennifer G Robinson

  • Jian Zhao

  • Corinne Hanotin

  • Stephen Donahue

Medical Centers

  • Univ of Montreal, Chicoutimi, QC, Canada

  • University of Iowa, Iowa City, IA

  • University of Cologne, Cologne, DE, Germany

  • Louisville Metabolic and Atherosclerosis Res Ctr Inc. L-MARC Res Ctr, Louisville, KY

  • Univ Hosp Vall -Hebron, Barcelona, Spain

  • Maine Res Associates, Auburn, ME

  • Royal Perth Hosp, Crawley, Australia

Locations

  • Canada

  • Germany

  • Spain

  • Australia

  • United States

Companies

  • Regeneron Pharmaceut

  • Sanofi S.A.

Study Components

Therapeutic Area

  • Endocrine/metabolic Diseases (ME)

Disease

  • Diabetes

Biomarkers

  • Nibrin

  • Proprotein convertase subtilisin/kexin type 9

Drug/Treatment

  • Atorvastatin

  • Rosuvastatin

  • Alirocumab

  • Ezetimibe

Outcome

  • N/A

Study Design

  • randomized

  • double blind/blinded

Phase

  • NA

Study Id's

  • NCT01730040

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved